ClinicalTrials.gg
CompletedNCT01995513PLATOUpdated Sep 18, 2023Results posted

Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients

A Phase 4 interventional study of Enzalutamide and Abiraterone in Prostate Cancer, sponsored by Pfizer. Completed at 95 sites in 11 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-18.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
509
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
16th of 125
509 · median 52
Started
2013
with 7 others
Phase 4
7 of 125
none open now
Registered
22nd of 125
by date
Lead sponsor
12 of 125
Pfizer

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 16th largest by enrollment, is one of 8 that started in 2013, is one of 7 in phase 4, and was the 22nd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine if continued treatment with Enzalutamide is effective in patients with metastatic prostate cancer.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men with castration-resistant prostate cancer
  • Progressive disease on androgen deprivation therapy
  • Patients must agree to continue androgen deprivation therapy with a GnRH agonist/antagonist throughout the study or have had a prior bilateral orchiectomy
  • performance score ≤ 1
  • Estimated of ≥ 12 months

Exclusion criteria

Exclusion Criteria:

  • Prior cytotoxic chemotherapy, aminoglutethimide, ketoconazole, abiraterone, or enzalutamide for the treatment of prostate cancer
  • Prior participation in a clinical trial of an agent that inhibits the androgen receptor or androgen synthesis (unless the treatment was placebo)
  • History of , active or seizure
  • Severe cardiovascular or hepatic disease
  • Pituitary or adrenal dysfunction
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
509 participants (actual)

Study arms

  • Experimental
    Enzalutamide & Abiraterone/prednisone

    Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with abiraterone (1000 mg) administered as four 250-mg tablets by mouth once daily and prednisone (10 mg) administered as one 5-mg tablet by mouth twice daily

    Drug: Enzalutamide · Drug: Abiraterone · Drug: Prednisone

  • Active comparator
    Enzalutamide placebo & Abiraterone/prednisone

    Enzalutamide placebo (placebo) capsules (identical in appearance to enzalutamide) administered as 4 capsules by mouth once daily in combination with abiraterone (1000 mg) administered as four 250-mg tablets by mouth once daily and prednisone (10 mg) administered as one 5-mg tablet by mouth twice daily.

    Drug: Abiraterone · Drug: Placebo for Enzalutamide · Drug: Prednisone

Interventions

  • 160 mg by mouth once daily

    Also known as: MDV3100, Xtandi

  • 1000 mg by mouth once daily

    Also known as: Abiraterone acetate, Zytiga

  • DrugPlacebo for Enzalutamide

    Sugar pill manufactured to mimic Enzalutamide 40 mg capsule

  • 5 mg by mouth twice daily

    Also known as: prednisolone

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS = time from randomization to first documentation of radiographic progression (RP),unequivocal clinical progression or death due to any cause (death within 112 days of treatment discontinuation without objective evidence of RP),whichever occurred first as per investigator. Unequivocal disease progression was pain requiring chronic administration of analgesics, decline of prostate cancer of Eastern Cooperative Oncology Group (ECOG) performance status score to 3 or higher or initiation of new anticancer therapy/radiation therapy or surgical intervention due to tumor progression. ECOG score range= 0(no severity) to 5(maximum severity).RP for bone disease was evaluated by appearance of 2 or more new bone lesions as per Prostate Cancer Clinical Trials Working Group 2 (PCWG2) or for soft tissue disease according to Response Evaluation Criteria in Solid Tumor version 1.1. Participants with no PFS event at analysis date were censored at last tumor assessment date prior to data cutoff date.

    Time frame: From randomization until disease progression, last tumor assessment without disease progression or death due to any cause, whichever occurred first (maximum up to 20.3 months)

Secondary outcomes

  1. Time to Prostate Specific Antigen (PSA) Progression

    Time from date of randomization to the date of first confirmed PSA progression as per Prostate Cancer Clinical Trials Working Group 2 (PCWG2). For participant's whose PSA decreased at Week 13 after randomization, progression was defined as 25 percent (%) PSA increase relative to nadir or absolute increase of \>=2 nanogram/milliliter (ng/mL) above nadir. Progression was confirmed if another assessment measured at least 3 weeks later met the criterion as well. For participant's whose PSA did not decrease at Week 13 after randomization, progression was defined as 25% PSA increase relative to baseline assessed 12 weeks after baseline. Participants who were not known to have had a PFS event at the analysis date were censored at last PSA assessment date prior to data cutoff date.

    Time frame: From randomization until disease progression, last tumor assessment without disease progression, whichever occurred first (maximum up to 11.1 months)

  2. Prostate Specific Antigen (PSA) Response Rate

    PSA response rate was defined as percentage of participants with \>=30% and \>=50% decrease in PSA from baseline at randomization to the maximal PSA response with a threshold of 30% and 50% respectively. PSA response was confirmed if another assessment measured at least 3 weeks later met the criterion as well.

    Time frame: From randomization until disease progression, last tumor assessment without disease progression, whichever occurred first (maximum up to 11.1 months)

  3. Objective Response Rate (ORR)

    Objective response rate as assessed by the investigator according to Response Evaluation Criteria in Solid Tumor version 1.1 (RECIST v1.1) was defined as 1) Percentage of participants with confirmed best overall complete response (CR) and partial response (PR); 2) Percentage of participants with CR, PR and stable disease (SD) for target lesions or non-progressive disease for non-target lesions. CR: Disappearance of all non-nodal target and non-target lesions, including target and non-target lymph nodes reduction to \<10 millimeter (mm) in short axis. No new lesions and disappearance of all non-target lesions. PR: \>= 30% decrease in sum of diameters of target lesions, compared to the sum at baseline. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions.

    Time frame: From randomization until CR or PR, whichever occurred first (maximum up to 21.3 months)

  4. Rate of Pain Progression

    Rate of pain progression was defined as percentage of participants with an increase of \>=30% from baseline in the mean Brief Pain Inventory-Short Form (BPI-SF) pain intensity item scores of 4 items assessing average, worst, least, and intermediate pain severity. BPI-SF is an 11-item self-report questionnaire that is designed to assess the severity and impact of pain on daily functions of a participant. BPI-sf includes 4 questions that assess pain intensity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). BPI-sf score range for each item was from 0=no pain to 10=worst possible pain. Total score was reported as average of individual questions ranges from 0 to 10, where lower scores indicated less pain or less pain interference.

    Time frame: Month 6

  5. Time to First Use of New Antineoplastic Therapy for Prostate Cancer

    It was defined as time from randomization to the date of first use of subsequent antineoplastic therapy for prostate cancer. For participants who had not started subsequent antineoplastic therapy as of data analysis cutoff date, the time to first use of subsequent antineoplastic therapy was censored at the date of last assessment.

    Time frame: From randomization until date of first use of any antineoplastic therapy (after last dose date of Period 2, maximum up to 22.3 months

  6. Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Global Score

    The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain, as well as a global quality of life score which is the sum of all 5 domain scores and ranges from 0 to 156 where higher scores represent better quality of life.

    Time frame: Baseline, Week 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89

  7. Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Social/Family Well-Being Domain Scores

    The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain. Total subscale score range for social/family well-being domain is from 0 (worst response) to 32 (best response), where higher score indicate better quality of life.

    Time frame: Baseline, Week 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89

  8. Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Emotional Well-Being Domain Scores

    The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain. Total subscale score range for emotional well-being domain is from 0 (worst response) to 24 (best response), where higher score indicate better quality of life.

    Time frame: Baseline, Week 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89

  9. Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Functional Well-Being Domain Scores

    The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain. Total subscale score range for functional well-being domain is from 0 (worst response) to 28 (best response), where higher score indicate better quality of life.

    Time frame: Baseline, Week 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89

  10. Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Prostate Cancer Domain Scores

    The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain. Total subscale score range for prostate cancer domain is from 0 (worst response) to 48 (best response), where higher score indicated better quality of life with fewer symptoms.

    Time frame: Baseline, Week 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89

  11. Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Physical Well-Being Domain Scores

    The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain. Total subscale score range for physical well-being domain is from 0 (worst response) to 28 (best response), where higher score indicate better quality of life.

    Time frame: Baseline, Week 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89

  12. Time to Degradation of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) Global Score

    Time to degradation of FACT-P was defined as the time from randomization to first assessment with at least a 10-point decrease from baseline in the global FACT-P score for each participant. The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, and functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain, as well as a global quality of life score which is the sum of all 5 domain scores and ranges from 0 to 156 with higher scores representing better quality of life. Participants with no score degradation at the time of analysis data cutoff were censored at the date of last assessment showing no degradation.

    Time frame: From randomization up to maximum of 18.4 months

Other outcomes

  1. Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent are events between first dose of study drug and up to 30 days after last dose of study drug that were absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious.

    Time frame: Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (maximum of 99.4 months)

  2. Percentage of Participants With Adverse Events (AEs) Leading to Study Drug Discontinuation

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Outcome of an AE was response to a question answered by the investigator: 'Is the AE leading to study discontinuation or death?' as 'yes'.

    Time frame: Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (maximum of 99.4 months)

  3. Percentage of Participants With Adverse Events (AEs) Leading to Death

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Outcome of an AE was response to a question answered by the investigator: 'Is the AE leading to study discontinuation or death?' as 'yes'.

    Time frame: Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (maximum of 99.4 months)

  4. Percentage of Participants With Treatment-Emergent Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state. Relatedness to study drug was assessed by the investigator.

    Time frame: Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (maximum of 99.4 months)

07

Results

Posted Nov 17, 2017

Participant flow

Period 1: First Open Label Treatment
Participant flow — Period 1: First Open Label Treatment
MilestoneEnzalutamide 160 mgEnzalutamide 160 mg Crossing Over to Abiraterone 1000 mg+ Prednisone 10 mgEnzalutamide 160 mg+ Abiraterone 1000 mg+ Prednisone 10mgPlacebo + Abiraterone 1000 mg+ Prednisone 10 mg
Started509000
Completed264000
Not completed245000
Withdrew: Other34000
Withdrew: Death14000
Withdrew: Adverse event40000
Withdrew: Failure to achieve psa response at week 1343000
Withdrew: Disease progression92000
Withdrew: Protocol non-compliance2000
Withdrew: Withdrawal by subject20000
Period 1: Second Open Label Treatment
Participant flow — Period 1: Second Open Label Treatment
MilestoneEnzalutamide 160 mgEnzalutamide 160 mg Crossing Over to Abiraterone 1000 mg+ Prednisone 10 mgEnzalutamide 160 mg+ Abiraterone 1000 mg+ Prednisone 10mgPlacebo + Abiraterone 1000 mg+ Prednisone 10 mg
Started01300
Completed0000
Not completed01300
Withdrew: Other0200
Withdrew: Disease progression01100
Period 2: Double Blind Treatment
Participant flow — Period 2: Double Blind Treatment
MilestoneEnzalutamide 160 mgEnzalutamide 160 mg Crossing Over to Abiraterone 1000 mg+ Prednisone 10 mgEnzalutamide 160 mg+ Abiraterone 1000 mg+ Prednisone 10mgPlacebo + Abiraterone 1000 mg+ Prednisone 10 mg
Started00126125
Treated00125124
Completed0000
Not completed00126125
Withdrew: Death0001
Withdrew: Other0033
Withdrew: Disease progression00104107
Withdrew: Adverse event00145
Withdrew: Withdrawal by subject0058
Withdrew: Protocol non-compliance0001

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS = time from randomization to first documentation of radiographic progression (RP),unequivocal clinical progression or death due to any cause (death within 112 days of treatment discontinuation without objective evidence of RP),whichever occurred first as per investigator. Unequivocal disease progression was pain requiring chronic administration of analgesics, decline of prostate cancer of Eastern Cooperative Oncology Group (ECOG) performance status score to 3 or higher or initiation of new anticancer therapy/radiation therapy or surgical intervention due to tumor progression. ECOG score range= 0(no severity) to 5(maximum severity).RP for bone disease was evaluated by appearance of 2 or more new bone lesions as per Prostate Cancer Clinical Trials Working Group 2 (PCWG2) or for soft tissue disease according to Response Evaluation Criteria in Solid Tumor version 1.1. Participants with no PFS event at analysis date were censored at last tumor assessment date prior to data cutoff date.

Time frame:
From randomization until disease progression, last tumor assessment without disease progression or death due to any cause, whichever occurred first (maximum up to 20.3 months)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsEnzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mgPlacebo+Abiraterone 1000mg+ Prednisone 10mg
Progression Free Survival (PFS)5.7 (4.6 to 8.1)5.6 (4.5 to 7.3)
Statistical analysis
  • Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg vs Placebo+Abiraterone 1000mg+ Prednisone 10mg · Log Rank · p = 0.2176 (P-value was based on log-rank test stratified by PSA response (greater than or equal to \[\>=\] 0 percent \[%\] to less than \[\<\] 30% vs \>=30%) at Week 13 in the open-label period.) · Hazard ratio (hr): 0.828 · 95% CI 0.612 to 1.119Hazard ratio was based on a Cox regression model (with treatment as the only covariate) stratified by PSA response (\>=0% to \<30% vs \>=30%) at Week 13 in the open-label period and is relative to Enzalutamide-placebo with \< 1 favoring Enzalutamide.
SecondaryTime to Prostate Specific Antigen (PSA) Progression

Time from date of randomization to the date of first confirmed PSA progression as per Prostate Cancer Clinical Trials Working Group 2 (PCWG2). For participant's whose PSA decreased at Week 13 after randomization, progression was defined as 25 percent (%) PSA increase relative to nadir or absolute increase of \>=2 nanogram/milliliter (ng/mL) above nadir. Progression was confirmed if another assessment measured at least 3 weeks later met the criterion as well. For participant's whose PSA did not decrease at Week 13 after randomization, progression was defined as 25% PSA increase relative to baseline assessed 12 weeks after baseline. Participants who were not known to have had a PFS event at the analysis date were censored at last PSA assessment date prior to data cutoff date.

Time frame:
From randomization until disease progression, last tumor assessment without disease progression, whichever occurred first (maximum up to 11.1 months)
Reported as:
Median · months
Time to Prostate Specific Antigen (PSA) Progression
monthsEnzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mgPlacebo+Abiraterone 1000mg+ Prednisone 10mg
Time to Prostate Specific Antigen (PSA) Progression2.8 (2.8 to 2.9)2.8 (2.8 to 2.8)
Statistical analysis
  • Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg vs Placebo+Abiraterone 1000mg+ Prednisone 10mg · Log Rank · p = 0.4500 (P-value was based on log-rank test stratified by PSA response (\>=0% to \<30% vs \>=30%) at Week 13 in the open-label period.) · Hazard ratio (hr): 0.874 · 95% CI 0.617 to 1.239Hazard ratio was based on a Cox regression model (with treatment as the only covariate) stratified by PSA response (\>=0% to \<30% vs \>=30%) at Week 13 in the open-label period and is relative to Enzalutamide-placebo with \< 1 favoring Enzalutamide.
SecondaryProstate Specific Antigen (PSA) Response Rate

PSA response rate was defined as percentage of participants with \>=30% and \>=50% decrease in PSA from baseline at randomization to the maximal PSA response with a threshold of 30% and 50% respectively. PSA response was confirmed if another assessment measured at least 3 weeks later met the criterion as well.

Time frame:
From randomization until disease progression, last tumor assessment without disease progression, whichever occurred first (maximum up to 11.1 months)
Reported as:
Number · percentage of participants
Prostate Specific Antigen (PSA) Response Rate
percentage of participantsEnzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mgPlacebo+Abiraterone 1000mg+ Prednisone 10mg
>= 50%0.8 (0.0 to 4.4)2.5 (0.5 to 7.0)
>= 30%2.4 (0.5 to 6.9)2.5 (0.5 to 7.0)
Statistical analysis
  • Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg vs Placebo+Abiraterone 1000mg+ Prednisone 10mg · Cochran-Mantel-Haenszel · p = 0.3101 (P-value was based on Cochran-Mantel-Haenszel mean score test stratified by PSA response (\>=0% to \<30% vs \>=30%) at Week 13 in the open-label period.) · Difference in response rate: -1.65 · 95% CI -4.82 to 1.51Difference in response rate was based upon standard normal approximation.
  • Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg vs Placebo+Abiraterone 1000mg+ Prednisone 10mg · Cochran-Mantel-Haenszel · p = 0.9917 (P-value was based on Cochran-Mantel-Haenszel mean score test stratified by PSA response (\>=0% to \<30% vs \>=30%) at Week 13 in the open-label period.) · Difference in response rate: -0.04 · 95% CI -3.90 to 3.82Difference in response rate was based upon standard normal approximation.
SecondaryObjective Response Rate (ORR)

Objective response rate as assessed by the investigator according to Response Evaluation Criteria in Solid Tumor version 1.1 (RECIST v1.1) was defined as 1) Percentage of participants with confirmed best overall complete response (CR) and partial response (PR); 2) Percentage of participants with CR, PR and stable disease (SD) for target lesions or non-progressive disease for non-target lesions. CR: Disappearance of all non-nodal target and non-target lesions, including target and non-target lymph nodes reduction to \<10 millimeter (mm) in short axis. No new lesions and disappearance of all non-target lesions. PR: \>= 30% decrease in sum of diameters of target lesions, compared to the sum at baseline. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions.

Time frame:
From randomization until CR or PR, whichever occurred first (maximum up to 21.3 months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsEnzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mgPlacebo+Abiraterone 1000mg+ Prednisone 10mg
CR + PR0.0 (0.00 to 9.25)5.0 (0.61 to 16.92)
CR + PR + SD68.4 (51.35 to 82.50)57.5 (40.89 to 72.96)
Statistical analysis
  • Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg vs Placebo+Abiraterone 1000mg+ Prednisone 10mg · Cochran-Mantel-Haenszel · p = 0.1653 (P-value was based on Cochran-Mantel-Haenszel mean score test stratified by PSA response (\>=0% to \<30% vs \>=30%) at Week 13 in the open-label period.) · Difference in objective response rate: -5.00 · 95% CI -11.75 to 1.75Difference in objective response rate was based upon standard normal approximation.
  • Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg vs Placebo+Abiraterone 1000mg+ Prednisone 10mg · Cochran-Mantel-Haenszel · p = 0.3216 (P-value was based on Cochran-Mantel-Haenszel mean score test stratified by PSA response (\>=0% to \<30% vs \>=30%) at Week 13 in the open-label period.) · Difference in objective response rate: 10.92 · 95% CI -10.37 to 32.21Difference in objective response rate was based upon standard normal approximation.
SecondaryRate of Pain Progression

Rate of pain progression was defined as percentage of participants with an increase of \>=30% from baseline in the mean Brief Pain Inventory-Short Form (BPI-SF) pain intensity item scores of 4 items assessing average, worst, least, and intermediate pain severity. BPI-SF is an 11-item self-report questionnaire that is designed to assess the severity and impact of pain on daily functions of a participant. BPI-sf includes 4 questions that assess pain intensity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). BPI-sf score range for each item was from 0=no pain to 10=worst possible pain. Total score was reported as average of individual questions ranges from 0 to 10, where lower scores indicated less pain or less pain interference.

Time frame:
Month 6
Reported as:
Number · percentage of participants
Rate of Pain Progression
percentage of participantsEnzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mgPlacebo+Abiraterone 1000mg+ Prednisone 10mg
Rate of Pain Progression36.2 (24.0 to 49.9)27.1 (16.4 to 40.3)
Statistical analysis
  • Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg vs Placebo+Abiraterone 1000mg+ Prednisone 10mg · Cochran-Mantel-Haenszel · p = 0.2963 (P-value was based on Cochran-Mantel-Haenszel mean score test stratified by PSA response (\>=0% to \<30% vs \>=30%) at Week 13 in the open-label period.) · Difference in progression rate: 9.09 · 95% CI -7.69 to 25.87Difference in Progression Rate was based upon normal approximation.
SecondaryTime to First Use of New Antineoplastic Therapy for Prostate Cancer

It was defined as time from randomization to the date of first use of subsequent antineoplastic therapy for prostate cancer. For participants who had not started subsequent antineoplastic therapy as of data analysis cutoff date, the time to first use of subsequent antineoplastic therapy was censored at the date of last assessment.

Time frame:
From randomization until date of first use of any antineoplastic therapy (after last dose date of Period 2, maximum up to 22.3 months
Reported as:
Median · months
Time to First Use of New Antineoplastic Therapy for Prostate Cancer
monthsEnzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mgPlacebo+Abiraterone 1000mg+ Prednisone 10mg
Time to First Use of New Antineoplastic Therapy for Prostate Cancer10.3 (8.7 to 12.1)8.6 (7.4 to 11.7)
Statistical analysis
  • Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg vs Placebo+Abiraterone 1000mg+ Prednisone 10mg · Log Rank · p = 0.3818 (P-value was based on log-rank test stratified by PSA response (\>=0% to \<30% vs \>=30%) at Week 13 in the open-label period.) · Hazard ratio (hr): 0.861 · 95% CI 0.616 to 1.204Hazard ratio was based on a Cox regression model (with treatment as the only covariate) stratified by PSA response (\>=0% to \<30% vs \>=30%) at Week 13 in the open-label period and is relative to Enzalutamide-placebo with \< 1 favoring Enzalutamide.
SecondaryChange From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Global Score

The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain, as well as a global quality of life score which is the sum of all 5 domain scores and ranges from 0 to 156 where higher scores represent better quality of life.

Time frame:
Baseline, Week 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89
Reported as:
Mean · units on a scale
Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Global Score
units on a scaleEnzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mgPlacebo+Abiraterone 1000mg+ Prednisone 10mg
Baseline116.4 ± 20.10119.0 ± 19.08
Change at Week 9-3.3 ± 14.90-2.2 ± 13.90
Change at Week 13-4.4 ± 14.44-0.5 ± 13.02
Change at Week 17-3.7 ± 12.40-2.3 ± 13.90
Change at Week 21-2.5 ± 12.33-2.7 ± 13.57
Change at Week 25-3.1 ± 13.47-2.1 ± 10.87
Change at Week 29-6.8 ± 13.980.3 ± 12.10
Change at Week 33-5.9 ± 15.35-0.2 ± 12.90
Change at Week 37-6.1 ± 14.250.9 ± 12.57
Change at Week 41-5.7 ± 12.171.3 ± 14.13
Change at Week 45-6.0 ± 9.56-2.6 ± 16.27
Change at Week 49-4.2 ± 11.361.8 ± 10.74
Change at Week 53-4.8 ± 10.171.8 ± 14.68
Change at Week 57 (n =17, 13)-4.3 ± 9.730.1 ± 7.45
Change at Week 61-5.5 ± 10.630.6 ± 12.94
Change at Week 65-7.0 ± 7.861.9 ± 9.50
Change at Week 69-3.5 ± 11.374.4 ± 13.29
Change at Week 73-0.7 ± 7.26-35.0 ± NA
Change at Week 77-4.0 ± 9.816.5 ± 30.41
Change at Week 8110.8 ± 9.24—
Change at Week 85-5.5 ± 3.54—
Change at Week 89-2.0 ± NA—
SecondaryChange From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Social/Family Well-Being Domain Scores

The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain. Total subscale score range for social/family well-being domain is from 0 (worst response) to 32 (best response), where higher score indicate better quality of life.

Time frame:
Baseline, Week 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89
Reported as:
Mean · units on a scale
Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Social/Family Well-Being Domain Scores
units on a scaleEnzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mgPlacebo+Abiraterone 1000mg+ Prednisone 10mg
Baseline22.1 ± 5.8022.4 ± 4.84
Change at Week 9-0.5 ± 4.33-0.8 ± 4.13
Change at Week 13-0.4 ± 3.46-0.4 ± 3.86
Change at Week 17-0.1 ± 3.68-0.6 ± 4.64
Change at Week 21-0.5 ± 3.24-1.2 ± 5.75
Change at Week 250.1 ± 2.79-1.0 ± 5.25
Change at Week 29-0.1 ± 3.20-0.2 ± 5.18
Change at Week 33-0.2 ± 3.210.0 ± 4.95
Change at Week 37-0.8 ± 3.040.8 ± 2.79
Change at Week 41-1.4 ± 3.75-0.1 ± 3.51
Change at Week 45-0.9 ± 3.36-0.8 ± 3.75
Change at Week 49-0.6 ± 2.880.0 ± 2.65
Change at Week 53-1.0 ± 3.150.4 ± 2.56
Change at Week 57-2.0 ± 3.060.2 ± 1.29
Change at Week 61-1.5 ± 2.77-0.2 ± 1.80
Change at Week 65-1.5 ± 2.54-0.5 ± 0.96
Change at Week 69-1.4 ± 2.03-0.5 ± 0.96
Change at Week 73-0.6 ± 3.22-1.0 ± NA
Change at Week 77-0.9 ± 3.41-0.5 ± 0.71
Change at Week 816.2 ± 5.42—
Change at Week 85-1.0 ± 1.41—
Change at Week 890.0 ± NA—
SecondaryChange From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Emotional Well-Being Domain Scores

The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain. Total subscale score range for emotional well-being domain is from 0 (worst response) to 24 (best response), where higher score indicate better quality of life.

Time frame:
Baseline, Week 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89
Reported as:
Mean · units on a scale
Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Emotional Well-Being Domain Scores
units on a scaleEnzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mgPlacebo+Abiraterone 1000mg+ Prednisone 10mg
Baseline18.1 ± 3.8018.5 ± 4.06
Change at Week 9-0.1 ± 2.810.1 ± 3.40
Change at Week 13-0.1 ± 3.550.2 ± 3.09
Change at Week 17-0.2 ± 3.440.4 ± 2.88
Change at Week 210.3 ± 3.480.1 ± 3.36
Change at Week 250.3 ± 2.580.3 ± 3.33
Change at Week 29-0.5 ± 3.560.3 ± 3.27
Change at Week 330.1 ± 3.330.9 ± 2.99
Change at Week 37-0.7 ± 4.040.9 ± 2.49
Change at Week 410.1 ± 2.991.4 ± 2.60
Change at Week 45-0.5 ± 3.231.2 ± 2.76
Change at Week 490.0 ± 3.001.3 ± 2.75
Change at Week 530.1 ± 2.721.2 ± 3.23
Change at Week 57-0.4 ± 2.321.6 ± 2.53
Change at Week 61-0.3 ± 3.141.1 ± 3.62
Change at Week 65-0.9 ± 3.572.9 ± 2.54
Change at Week 69-0.5 ± 2.931.5 ± 2.93
Change at Week 731.0 ± 2.83-5.0 ± 5.66
Change at Week 770.1 ± 2.672.0 ± 2.83
Change at Week 811.5 ± 3.54—
Change at Week 85-1.5 ± 0.71—
Change at Week 89-3.0 ± NA—
SecondaryChange From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Functional Well-Being Domain Scores

The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain. Total subscale score range for functional well-being domain is from 0 (worst response) to 28 (best response), where higher score indicate better quality of life.

Time frame:
Baseline, Week 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89
Reported as:
Mean · units on a scale
Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Functional Well-Being Domain Scores
units on a scaleEnzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mgPlacebo+Abiraterone 1000mg+ Prednisone 10mg
Baseline20.2 ± 5.5420.3 ± 5.84
Change at Week 9-1.0 ± 4.23-0.7 ± 4.62
Change at Week 13-1.2 ± 4.07-0.4 ± 4.54
Change at Week 17-1.3 ± 4.00-0.5 ± 4.11
Change at Week 21-1.2 ± 5.03-0.7 ± 4.03
Change at Week 25-1.0 ± 3.41-0.3 ± 4.41
Change at Week 29-2.4 ± 4.67-0.2 ± 4.38
Change at Week 33-2.0 ± 5.14-0.7 ± 4.49
Change at Week 37-1.5 ± 5.220.2 ± 5.72
Change at Week 41-2.1 ± 4.440.8 ± 5.74
Change at Week 45-2.0 ± 3.37-0.3 ± 6.28
Change at Week 49-2.1 ± 4.551.5 ± 5.02
Change at Week 53-1.6 ± 4.671.3 ± 4.92
Change at Week 57-1.4 ± 4.062.0 ± 4.37
Change at Week 61-0.8 ± 3.342.9 ± 5.56
Change at Week 65-1.2 ± 2.211.7 ± 2.75
Change at Week 690.2 ± 1.482.3 ± 4.23
Change at Week 73-0.6 ± 3.024.0 ± 12.73
Change at Week 77-1.6 ± 3.912.5 ± 9.19
Change at Week 81-1.5 ± 7.78—
Change at Week 85-1.5 ± 2.12—
Change at Week 891.0 ± NA—
SecondaryChange From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Prostate Cancer Domain Scores

The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain. Total subscale score range for prostate cancer domain is from 0 (worst response) to 48 (best response), where higher score indicated better quality of life with fewer symptoms.

Time frame:
Baseline, Week 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89
Reported as:
Mean · units on a scale
Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Prostate Cancer Domain Scores
units on a scaleEnzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mgPlacebo+Abiraterone 1000mg+ Prednisone 10mg
Baseline33.2 ± 6.8534.2 ± 6.45
Change at Week 9-0.7 ± 5.97-0.9 ± 5.18
Change at Week 13-1.9 ± 5.91-0.1 ± 5.36
Change at Week 17-1.0 ± 5.36-1.4 ± 5.10
Change at Week 21-0.4 ± 5.13-0.6 ± 4.83
Change at Week 25-0.8 ± 6.93-0.8 ± 4.42
Change at Week 29-1.3 ± 5.75-0.3 ± 4.77
Change at Week 33-1.4 ± 5.16-0.6 ± 4.88
Change at Week 37-1.5 ± 4.88-0.8 ± 4.32
Change at Week 41-1.0 ± 5.13-0.7 ± 5.34
Change at Week 45-0.8 ± 4.88-1.7 ± 7.02
Change at Week 49-0.8 ± 4.26-0.9 ± 4.63
Change at Week 53-1.1 ± 3.65-1.8 ± 5.78
Change at Week 57-0.5 ± 3.67-3.3 ± 4.48
Change at Week 61-2.1 ± 4.29-3.1 ± 5.68
Change at Week 65-2.0 ± 4.05-2.6 ± 6.32
Change at Week 69-1.5 ± 3.301.1 ± 5.79
Change at Week 73-0.2 ± 3.17-6.4 ± 9.32
Change at Week 77-1.0 ± 3.71-1.5 ± 13.44
Change at Week 813.1 ± 1.22—
Change at Week 85-0.5 ± 0.71—
Change at Week 890.0 ± NA—
SecondaryChange From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Physical Well-Being Domain Scores

The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain. Total subscale score range for physical well-being domain is from 0 (worst response) to 28 (best response), where higher score indicate better quality of life.

Time frame:
Baseline, Week 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89
Reported as:
Mean · units on a scale
Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Physical Well-Being Domain Scores
units on a scaleEnzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mgPlacebo+Abiraterone 1000mg+ Prednisone 10mg
Baseline22.9 ± 4.5023.6 ± 4.42
Change at Week 9-0.8 ± 4.040.1 ± 3.20
Change at Week 13-1.0 ± 4.110.0 ± 2.63
Change at Week 17-1.1 ± 3.26-0.3 ± 2.97
Change at Week 21-0.8 ± 3.11-0.8 ± 4.48
Change at Week 25-1.7 ± 4.23-0.4 ± 2.90
Change at Week 29-2.5 ± 4.890.3 ± 2.67
Change at Week 33-2.5 ± 5.370.1 ± 3.18
Change at Week 37-1.8 ± 4.500.4 ± 3.13
Change at Week 41-1.5 ± 3.940.4 ± 2.80
Change at Week 45-2.0 ± 3.72-0.4 ± 3.59
Change at Week 49-0.9 ± 3.780.6 ± 2.12
Change at Week 53-0.2 ± 3.780.7 ± 2.85
Change at Week 57-0.4 ± 3.250.4 ± 2.37
Change at Week 61-0.8 ± 3.110.4 ± 2.32
Change at Week 65-1.9 ± 4.250.4 ± 1.99
Change at Week 69-0.3 ± 4.08-0.5 ± 2.67
Change at Week 73-0.3 ± 2.05-3.0 ± 5.66
Change at Week 77-0.7 ± 2.814.0 ± 4.24
Change at Week 811.5 ± 2.12—
Change at Week 85-1.0 ± 0.00—
Change at Week 890.0 ± NA—
SecondaryTime to Degradation of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) Global Score

Time to degradation of FACT-P was defined as the time from randomization to first assessment with at least a 10-point decrease from baseline in the global FACT-P score for each participant. The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, and functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain, as well as a global quality of life score which is the sum of all 5 domain scores and ranges from 0 to 156 with higher scores representing better quality of life. Participants with no score degradation at the time of analysis data cutoff were censored at the date of last assessment showing no degradation.

Time frame:
From randomization up to maximum of 18.4 months
Reported as:
Median · months
Time to Degradation of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) Global Score
monthsEnzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mgPlacebo+Abiraterone 1000mg+ Prednisone 10mg
Time to Degradation of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) Global Score4.6 (3.7 to 6.5)6.4 (5.5 to 13.9)
Statistical analysis
  • Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg vs Placebo+Abiraterone 1000mg+ Prednisone 10mg · Log Rank · p = 0.0739 (P-value was based on log-rank test stratified by PSA response (\>=0% to \<30% vs \>=30%) at Week 13 in the open-label period) · Hazard ratio (hr): 1.399 · 95% CI 0.967 to 2.025Hazard ratio was based on a Cox regression model (with treatment as the only covariate) stratified by PSA response (\>=0% to \<30% vs \>=30%) at Week 13 in the open-label period and is relative to Enzalutamide-placebo with \< 1 favoring Enzalutamide.
Other pre-specifiedPercentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent are events between first dose of study drug and up to 30 days after last dose of study drug that were absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious.

Time frame:
Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (maximum of 99.4 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
percentage of participantsEnzalutamide 160 mgEnzalutamide Crossing Over to Abiraterone + PrednisoneEnzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mgPlacebo+Abiraterone 1000mg+ Prednisone 10mg
AEs93.510091.292.7
SAEs32.030.837.629.8
Other pre-specifiedPercentage of Participants With Adverse Events (AEs) Leading to Study Drug Discontinuation

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Outcome of an AE was response to a question answered by the investigator: 'Is the AE leading to study discontinuation or death?' as 'yes'.

Time frame:
Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (maximum of 99.4 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) Leading to Study Drug Discontinuation
percentage of participantsEnzalutamide 160 mgEnzalutamide Crossing Over to Abiraterone + PrednisoneEnzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mgPlacebo+Abiraterone 1000mg+ Prednisone 10mg
Drug Discontinuation with Enzalutamide or Placebo11.8—23.211.3
Drug Discontinuation with Abiraterone—7.723.212.9
Drug Discontinuation with Prednisone—7.716.012.1
Other pre-specifiedPercentage of Participants With Adverse Events (AEs) Leading to Death

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Outcome of an AE was response to a question answered by the investigator: 'Is the AE leading to study discontinuation or death?' as 'yes'.

Time frame:
Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (maximum of 99.4 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) Leading to Death
percentage of participantsEnzalutamide 160 mgEnzalutamide Crossing Over to Abiraterone + PrednisoneEnzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mgPlacebo+Abiraterone 1000mg+ Prednisone 10mg
Percentage of Participants With Adverse Events (AEs) Leading to Death5.903.22.4
Other pre-specifiedPercentage of Participants With Treatment-Emergent Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)

Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state. Relatedness to study drug was assessed by the investigator.

Time frame:
Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (maximum of 99.4 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)
percentage of participantsEnzalutamide 160 mgEnzalutamide Crossing Over to Abiraterone + PrednisoneEnzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mgPlacebo+Abiraterone 1000mg+ Prednisone 10mg
TEAEs related to Enzalutamide or Placebo66.6—46.436.3
TEAEs related to Abiraterone—38.554.445.2
TEAEs related to Prednisone—7.736.032.3
SAEs related to Enzalutamide or Placebo4.1—7.24.8
SAEs related to Abiraterone—07.24.0
SAEs related to Prednisone—02.44.8

Adverse events

Collected over Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (maximum duration of exposure: 99.4 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enzalutamide 160 mg32/509 (6.3%)163/509 (32%)474/509 (93.1%)
Enzalutamide Crossing Over to Abiraterone + Prednisone1/13 (7.7%)4/13 (30.8%)13/13 (100%)
Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg14/126 (11.1%)47/125 (37.6%)113/125 (90.4%)
Placebo + Abiraterone 1000 mg + Prednisone 10mg10/125 (8%)37/124 (29.8%)113/124 (91.1%)
Most frequent serious events
Showing 10 of 229
Most frequent serious events
EventEnzalutamide 160 mgEnzalutamide Crossing Over to Abiraterone + PrednisoneEnzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mgPlacebo + Abiraterone 1000 mg + Prednisone 10mg
Myocardial ischaemiaCardiac disorders1/5091/131/1250/124
GastroenteritisInfections and infestations1/5091/130/1250/124
ArthralgiaMusculoskeletal and connective tissue disorders3/5091/131/1250/124
Neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/5091/130/1250/124
Spinal cord compressionNervous system disorders5/5090/135/1252/124
PneumoniaInfections and infestations7/5090/131/1253/124
Metastatic painNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/5090/133/1252/124
HaematuriaRenal and urinary disorders11/5090/133/1251/124
Myocardial infarctionCardiac disorders2/5090/130/1252/124
OsteonecrosisMusculoskeletal and connective tissue disorders0/5090/130/1252/124
Most frequent other events
Showing 10 of 735
Most frequent other events
EventEnzalutamide 160 mgEnzalutamide Crossing Over to Abiraterone + PrednisoneEnzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mgPlacebo + Abiraterone 1000 mg + Prednisone 10mg
FatigueGeneral disorders206/5090/1320/12519/124
Back painMusculoskeletal and connective tissue disorders112/5091/1326/12528/124
NauseaGastrointestinal disorders100/5090/1323/12512/124
HypertensionVascular disorders52/5090/1324/12511/124
Hot flushVascular disorders90/5091/138/1253/124
ConstipationGastrointestinal disorders84/5090/1322/12514/124
ArthralgiaMusculoskeletal and connective tissue disorders78/5092/1322/12516/124
Decreased appetiteMetabolism and nutrition disorders83/5092/1314/12511/124
FallInjury, poisoning and procedural complications51/5092/1314/12510/124
Rib fractureInjury, poisoning and procedural complications5/5092/131/1251/124

Baseline characteristics

ITT (Intent to treat) population included all participants randomly assigned to study treatment.

Age, Continuous
Age, Continuous(years)Enzalutamide 160 mg
Mean72.3 ± 8.31
Sex: Female, Male
Sex: Female, Male(Participants)Enzalutamide 160 mg
Female0
Male509
08

Study locations

95 sites
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02115, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • eResearch Technology
    Philadelphia, Pennsylvania 19103, United States
  • Urology of Virginia, PLLC
    Virginia Beach, Virginia 23462, United States
  • Border Medical Oncology Research Unit
    Albury, New South Wales 2640, Australia
  • Ramsay Health Care Australia Pty Ltd
    Albury, New South Wales 2640, Australia
  • Regional Imaging Border
    Albury, New South Wales 2640, Australia
  • Terry White Chemist
    Albury, New South Wales 2640, Australia
  • Concord Cancer Centre, Medical Oncology Department
    Concord, New South Wales 2139, Australia
  • Concord Hospital Clinical Trials Pharmacy
    Concord, New South Wales 2139, Australia
  • Epic Pharmacy Lismore
    Lismore, New South Wales 2480, Australia
  • Macquarie University Hospital Pharmacy
    North Ryde, New South Wales 2109, Australia
  • Macquarie University
    North Ryde, New South Wales 2109, Australia
  • Epic Pharmacy Port Macquarie base hospital
    Port Macquarie, New South Wales 2444, Australia
  • Port Macquarie Base Hospital,North Coast Cancer Institute
    Port Macquarie, New South Wales 2444, Australia
  • North Shore Radiology and Nuclear Medicine
    St Leonards, New South Wales 2065, Australia
  • Royal North Shore Hospital
    St Leonards, New South Wales 2065, Australia
  • Sydney Adventist Hospital
    Sydney, New South Wales 2076, Australia
  • Northern NSW Local Health District
    Tweed Heads, New South Wales 2485, Australia
  • Queensland Diagnostic Imaging
    Tweed Heads, New South Wales 2485, Australia
  • Sydney Adventist Hospital
    Wahroonga, New South Wales 2076, Australia
  • Regional Imaging
    West Albury, New South Wales 2640, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Icon Cancer Care Wesley
    Auchenflower, Queensland 4066, Australia
  • River City Pharmacy - APHS
    Auchenflower, Queensland 4066, Australia
  • Icon Cancer Care Chermside
    Chermside, Queensland 4032, Australia
  • Gold Coast Radiology PTY LTD
    Hope Island, Queensland 4212, Australia
  • Icon Cancer Care South Brisbane
    South Brisbane, Queensland 4101, Australia
  • Icon Cancer Care
    South Brisbane, Queensland 4101, Australia
  • South Coast Radiology
    Tugun, Queensland 4224, Australia
  • Adelaide Cancer Centre
    Kurralta Park, South Australia 5037, Australia
  • Ashford Cancer Centre Research
    Kurralta Park, South Australia 5037, Australia
  • Cancer Care SA Pty Ltd
    Kurralta Park, South Australia 5037, Australia
  • Tenpharm Pty Ltd trading as EPIC Pharmacy Tennyson
    Kurralta Park, South Australia 5037, Australia
  • Moorabbin Radiology
    Bentleigh East, Victoria 3165, Australia
  • Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • Cabrini Health - Cabrini Hospital
    Malvern, Victoria 3144, Australia
  • Border Medical Oncology
    Wodonga, Victoria 3690, Australia
  • Algemeen Ziekenhuis Groeninge
    Kortrijk, West-vlaanderen 8500, Belgium
  • Cliniques universitaires saint-Luc
    Bruxelles, 1200, Belgium
  • Universitaire Ziekenhuizen Leuven
    Leuven, 3000, Belgium
  • Rigshospitalet CPC 7521
    Copenhagen, Norrebro 2200, Denmark
  • Arhus Universitetshospital
    Arhus N, 8200, Denmark
  • Rigshospitalet
    Copenhagen, 2100, Denmark
  • Frederiksberg Hospital
    Frederiksberg, 2000, Denmark
  • Helsingin yliopistollinen keskussairaala, Meilahden sairaala
    Helsinki, 00290, Finland
  • Oulun yliopistollinen sairaala
    Oulu, 90220, Finland
  • Tampereen yliopistollinen Sairaala
    Tampere, 33520, Finland
  • Institut Gustave Roussy - Service d'Urologie
    Villejuif Cedex, 94805, France
  • U.O. Oncologia Medica, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura
    Meldola, FC 47014, Italy
  • Medicina Nucleare, Azienda Ospedaliera "Istituti Ospitalieri" di Cremona
    Cremona, 26100, Italy
  • Servizio di Radiologia, Azienda Ospedaliera "Istituti Ospitalieri" di Cremona
    Cremona, 26100, Italy
  • Struttura Complessa di Oncologia, Azienda Socio Sanitaria Territoriale di Cremona
    Cremona, 26100, Italy
  • Laboratorio Farmaci Antiblastici
    Meldola (FC), 47014, Italy
  • UO Radiologia
    Meldola (FC), 47014, Italy
  • SCDU Oncologia Medica II Pad, A.O.U. San Luigi Gonzaga
    Orbassano TO, 10043, Italy
  • SCDU Radiodiagnostica, A.O.U. San Luigi Gonzaga
    Orbassano TO, 10043, Italy
  • SS Medicina Nucleare, A.O.U. San Luigi Gonzaga
    Orbassano TO, 10043, Italy
  • Azienda Ospedaliera S. Camillo Forlanini, UOC per il governo clinico in Oncologia Medica
    Roma, 00152, Italy
  • UOC Radiologia Piasta, Azienda Ospedaliera S. Camillo Forlanini
    Roma, 00512, Italy
  • Fakultna nemocnica s poliklinikou F.D. Roosevelta
    Banska Bystrica, 975 17, Slovakia
  • Institut nuklearnej a molekularnej mediciny
    Banska Bystrica, 975 17, Slovakia
  • Fakultna nemocnica s poliklinikou F.D. Roosevelta
    Banska Bystrica, 97517, Slovakia
  • Bratislavske radiodiagnosticke centrum,a.s.
    Bratislava, 814 99, Slovakia
  • CUIMED, s.r.o., urologicka ambulancia
    Bratislava, 851 05, Slovakia
  • Univerzitna nemocnica martin
    Martin, 036 59, Slovakia
  • Jessenius-diagnosticke centrum, a.s.
    Nitra, 949 01, Slovakia
  • Uroexam, spol. s r.o., Urologicka ambulancia
    Nitra, 949 01, Slovakia
  • IZOTOPCENTRUM, s.r.o.
    Nitra, 950 01, Slovakia
  • GAMMALAB, spol.s r.o., Oddelenie nuklearnej mediciny
    Trnava, 917 01, Slovakia
  • ICO Badalona-Instituto Germans Trias i Pujol
    Badalona,, Barcelona 08916, Spain
  • CO Badalona-Instituto Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
  • ALTAHIA, Xarxa Assistencial Universitaria de Manresa
    Manresa, Barcelona 08243, Spain
  • Hospital Universitari Parc Tauli
    Sabadell, Barcelona 08208, Spain
  • ICO Badalona-Instituto Germans Trias i Pujol
    Badalona,, Barcelon 08916, Spain
  • Hospital Universitario Son Espases
    Palma, Islas Baleares 07120, Spain
  • Hospital del Mar
    Barcelona, 08003, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario Madrid Sanchinarro
    Madrid, 28050, Spain
  • Urologmottagningen
    Goteborg, 41345, Sweden
  • Urologiska kliniken
    Malmo, 20502, Sweden
  • Oriola
    Molnlycke, 435 25, Sweden
  • Apoteket AB Kliniska Provningar Molnlycke
    Molnlycke, 435 33, Sweden
  • Rontgenkliniken
    Orebro, 701 85, Sweden
  • Urologmottagningen
    Orebro, 701 85, Sweden
  • East and North Hertfordshire NHS Trust
    Northwood, Middlesex HA6 2RN, United Kingdom
  • The Royal Marsden NHS Foundation Trust
    Sutton, Surrey SM2 5PT, United Kingdom
  • Velindre NHS Trust
    Cardiff, CF14 2TL, United Kingdom
  • University College Hospitals NHS Trust
    London, NW1 2BU, United Kingdom
  • The Royal Marsden NHS Foundation Trust
    London, SW3 6JJ, United Kingdom
  • University College London Hospitals NHS Foundation Trust
    London, WC1E 6AG, United Kingdom
  • Oxford University Hospitals NHS Trust
    Oxford, OX3 7LE, United Kingdom
09

References and documents

Publications

  • Attard G, Borre M, Gurney H, Loriot Y, Andresen-Daniil C, Kalleda R, Pham T, Taplin ME; PLATO collaborators. Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment. J Clin Oncol. 2018 Sep 1;36(25):2639-2646. doi: 10.1200/JCO.2018.77.9827. Epub 2018 Jul 20. PubMed 30028657 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2013 to primary completion in Nov 2016, 36 months.

Results were first posted in Nov 2017, 1 year after primary completion.

Of 52 phase 4 interventional studies under Prostatic Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2013
First posted
Nov 26, 2013
StartActual
Oct 22, 2013
Primary completionActual
Nov 15, 2016
CompletionActual
Aug 31, 2022
Results first posted
Nov 17, 2017
Last update
Sep 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01995513
Lead sponsor
Pfizer
Collaborators
Astellas Pharma Inc, Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Responsible party
Sponsor
First posted
Nov 26, 2013
Start date
Oct 22, 2013
Primary completion
Nov 15, 2016
Completion
Aug 31, 2022
Results posted
Nov 17, 2017
Last update
Sep 18, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
Medical Director
study director · Medviation, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion